Wealthcare Advisory Partners LLC Lowers Position in Kenvue Inc. (NYSE:KVUE)

Wealthcare Advisory Partners LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,146 shares of the company’s stock after selling 615 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Kenvue were worth $606,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC purchased a new position in shares of Kenvue during the third quarter worth about $5,053,000. Cambridge Investment Research Advisors Inc. purchased a new position in Kenvue in the 3rd quarter worth approximately $1,809,000. IFM Investors Pty Ltd purchased a new position in Kenvue in the 3rd quarter worth approximately $6,200,000. Park Avenue Securities LLC bought a new position in shares of Kenvue in the 3rd quarter worth $308,000. Finally, Graypoint LLC purchased a new stake in shares of Kenvue during the 3rd quarter valued at $265,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $20.45 on Thursday. The company’s 50 day moving average price is $19.87 and its 200-day moving average price is $20.12. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. The company’s revenue for the quarter was down 24.9% on a year-over-year basis. On average, sell-side analysts forecast that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 3.91%.

Analyst Ratings Changes

Several research analysts recently issued reports on KVUE shares. HSBC upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday. JPMorgan Chase & Co. cut their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. Royal Bank of Canada dropped their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Finally, William Blair initiated coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.